MICHAEL J MERRY

Eye and Vision Services Providers|Optometrist CHICO, CA NPI 1669725008

General Payments — all program years on this page

$2,763.41

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 77
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $439.42 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $439.4218

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
BIOTISSUE HOLDINGS INC. $289.3012
Sight Sciences, Inc. $60.932
Tarsus Pharmaceuticals, Inc. $54.643
ABBVIE INC. $34.551

By program year

Program yearAmountRecords
2018 $565.6817
2019 $146.084
2020 $221.818
2021 $376.546
2022 $499.7712
2023 $514.1112
2024 $439.4218

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1105025962 ABBVIE INC. $34.55 04/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139117186 Tarsus Pharmaceuticals, Inc. $20.04 02/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139117188 Tarsus Pharmaceuticals, Inc. $16.29 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139117190 Tarsus Pharmaceuticals, Inc. $18.31 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148761509 BIOTISSUE HOLDINGS INC. $19.60 09/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148765514 BIOTISSUE HOLDINGS INC. $27.00 08/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148770960 BIOTISSUE HOLDINGS INC. $59.74 06/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148773046 BIOTISSUE HOLDINGS INC. $48.83 05/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148776413 BIOTISSUE HOLDINGS INC. $32.33 04/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148779277 BIOTISSUE HOLDINGS INC. $24.58 03/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148779285 BIOTISSUE HOLDINGS INC. $2.79 03/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148779291 BIOTISSUE HOLDINGS INC. $0.65 03/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148782349 BIOTISSUE HOLDINGS INC. $31.35 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148782359 BIOTISSUE HOLDINGS INC. $2.88 12/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148782363 BIOTISSUE HOLDINGS INC. $20.88 12/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148785993 BIOTISSUE HOLDINGS INC. $18.67 02/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151937179 Sight Sciences, Inc. $20.63 01/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151937181 Sight Sciences, Inc. $40.30 11/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.